Amicus hit hard on FDA advice for more migalastat work before NDA
This article was originally published in Scrip
Shares of Amicus Therapeutics tumbled as low as 28% on 17 June after the firm's CEO disclosed the company would not seek approval of its Fabry disease drug migalastat until the second half of next year, at the earliest – revealing the FDA advised the firm to first complete its other Phase III study.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.